Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Excretion of [¹⁴C]Opevesostat in Healthy Men
NCT06566989Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of opevesostat in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Merck & Co. Primary endpoints: Cumulative amount of total radioactivity excreted in urine (CumAeu) up to 8 days, Cumulative amount of total radioactivity excreted in feces (CumAef) up to 8 days and 9 more. Started Sep 2024; status: completed.
02
Drugs
opevesostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06566989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06566989.